2018
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.Peer-Reviewed Original Research
2016
Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis
Magnuson W, Amini A, Patil T, Kavanagh B, Camidge D, Braunstein S, Boreta L, Attia A, Rana N, Contessa J, Gettinger S, Lester-Coll N, Yu J, Chiang V. Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s57-s58. DOI: 10.1016/j.ijrobp.2016.06.149.Peer-Reviewed Original ResearchImpact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 95: 673-679. PMID: 27034176, DOI: 10.1016/j.ijrobp.2016.01.037.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyUpfront EGFR-TKIIntracranial progression-free survivalUpfront radiation therapyProgression-free survivalBrain metastasesEGFR-TKI groupEGFR-TKIEGFR-mutant NSCLCOverall survivalRadiation therapyEpidermal Growth Factor Receptor–Mutant NonDisease-specific Graded Prognostic AssessmentUpfront EGFR tyrosine kinase inhibitorsEGFR-TKI resistance mutationSmall cell lung cancerEGFR tyrosine kinase inhibitorsEGFR-TKI useMedian overall survivalSimilar overall survivalUpfront RT groupInferior overall survivalCell lung cancerMutant lung adenocarcinomaEpidermal growth factor receptorCeritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer
Qian J, Yu J, Gettinger S, Chiang V. Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer. Cancer Treatment And Research Communications 2016, 6: 17-19. DOI: 10.1016/j.ctrc.2016.02.002.Peer-Reviewed Original ResearchNon-small cell lung cancerAnaplastic lymphoma kinaseWhole-brain radiation therapySymptomatic brain metastasesBrain radiation therapyCell lung cancerBrain metastasesStereotactic radiosurgerySystemic therapyLung cancerRadiation therapyActive small-molecule tyrosine kinase inhibitorLarge symptomatic brain metastasisNext-generation ALK inhibitorsSmall molecule tyrosine kinase inhibitorsYear old Caucasian femaleMolecule tyrosine kinase inhibitorsGeneration ALK inhibitorsALK inhibitor crizotinibOld Caucasian femaleKey driver mutationsTyrosine kinase inhibitorsLocal therapyInhibitor crizotinibALK inhibitors
2012
Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial
Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial. Journal Of Clinical Oncology 2012, 30: 3953-3959. PMID: 23045594, DOI: 10.1200/jco.2012.41.9820.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDisease-Free SurvivalDrug Administration ScheduleErlotinib HydrochlorideEsophagitisEsophagusFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingQuinazolinesRadiotherapy, ConformalRemission InductionTracheoesophageal FistulaTreatment FailureConceptsPhase I/II trialCell lung cancerConsolidation therapyII trialLung cancerObjective response rateUse of bevacizumabPhase I portionStage III NSCLCCombined modality treatmentOverall survival timeConformal radiation therapyEsophageal toxicityConcurrent chemoradiotherapyConcurrent chemotherapyEligible patientsInduction chemotherapyPrincipal toxicityEfficacy signalsCohort 2Cohort 1I portionBevacizumabRadiation therapySurvival time
2008
Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope
Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Current Opinion In Oncology 2008, 20: 19-24. PMID: 18043252, DOI: 10.1097/cco.0b013e3282f28373.Peer-Reviewed Original ResearchConceptsThyroid cancerClinical trialsAdvanced thyroid tumorsAdvanced thyroid cancerFurther clinical trialsMedullary thyroid cancerRandomized clinical trialsAblative radiation therapyEpidermal growth factor receptorInhibitors of angiogenesisGrowth factor receptorChemotherapy optionsMedical oncologistsEndocrine tumorsConventional chemotherapyRET inhibitionEndocrine cancersEndocrine malignancyRadiation therapyThyroid tumorsAntiangiogenesis strategiesNatural historyCancerFactor receptorRET protein